REFERENCES


Disclosed Interests: None declared


AB0323 CARDIOVASCULAR RISK ESTIMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS OR C-DMARDS

Evangelia Mole1, Soussana Gag1, Dimitra Moschou1, Georgia Mpail1, Stavros Theodorakopoulos1, Konstantina Zoupidou1, Nikolaos Kontodimopoulos2. 1KAT General Hospital of Attica, Department of Rheumatology, Athens, Greece; 2KAT General Hospital of Attica, Division of Management, Athens, Greece

Background: Patients with Rheumatoid Arthritis (RA) are at increased risk of developing atherosclerotic cardiovascular (CV) disease. The impact of treatment with conventional or biological disease modifying drugs (c- or b-DMARDS) on inflammation of systemic circulation is an important question.

Objectives: The aim of this study is to determine the influence of therapy (c-DMARDS or b-DMARDS) on 10 year CV risk in patients with RA over a period of 18 months.

Methods: A single center, observational study of 229 consecutive RA patients, who were treated with c-DMARDS or b-DMARDS mono/combination therapy for at least 18 months. The 10 year CV risk was calculated with Framingham risk score (FRS).

Results: A total of 229 patients were included, 111 received b-DMARDS and 194 c-DMARDS. The mean age was comparable between 2 groups (62.45±12.74 vs 64.56±12.48 years, p=0.1596) and 148 (64.63%) were females. Patients receiving b-DMARDS had longer disease duration compared to c-DMARDS group (14.34±9.89 vs 9.99±9.3 years respectively, p=0.001) and compared to baseline FRS 10-year percent CV risk (10.74±8.88 vs 11.68±8.78 respectively, p=0.3710). Baseline patient distribution across intermediate (9.6% vs 16.6%) and high (10.91% vs 16.16%) FRS 10-year CV risk categories was comparable between treatment groups (b-DMARDS vs c-DMARDS, p=0.208), except low FRS category (27.51% vs 51.53% respectively, p=0.001). At month 18, FRS 10-year CV risk category remained stable in c-DMARDS patients (low: 31.88%, intermediate: 10.92%, high: 5.24%, p=0.47), whereas a significant shift in FRS 10-year CV risk category was observed in c-DMARDS patients (low: 58.1%, intermediate: 17.03%, high: 9.17%, p=0.001). Within-group the mean (SD) change in FRS 10-year percent CV risk from baseline to month 18 was statistically significant for both b-DMARDS (Δ: 10.74-6.94= 3.97 (1.14), p=0.001) and c-DMARDS (Δ: 11.68-8.73 = 2.95 (0.91), p<0.001).

Conclusion: Patients treated with b-DMARDS had lower baseline and month 18 10-year CV risk. However, both treatment arms induced significant improvement of 10-year CV risk at 18 months.

REFERENCES

[1] Ann M. Chodara, MD, Aimée Wattiaux, BS, and Christie M. Bartels, MD, “Assessment of pain improvement during treatment for Rheumatoid Arthritis (RA) may be useful to clinical decision between providers and their patients (pts).”

Baricitinib (BARI) once daily, an oral, selective Janus Kinase (JAK)1/JAK2 inhibitor, reduced disease activity levels in Rheumatoid Arthritis (RA) patients (pts) with an inadequate response (IR) to methotrexate (MTX).

Objectives: To evaluate the likelihood of achieving different levels of pain control with BARI 2 mg or 4 mg in patients with RA with inadequate response to traditional DMARDs or biological DMARDs.

Methods: Prospective observational registry of pts with RA who start treatment with BARI, in a third level Spanish Hospital (October 2017- June 2018). BARI 2 mg is started in patients with inadequate response to traditional DMARDs and BARI 4 mg in patients with inadequate response to biological DMARDs. The pts were assessment of pain was assessed with 0-100 mm visual analog scale (VAS) at each study visit. The likelihood of achieving >25%, >50% and >70% pain VAS improvement through week 12 and analyze if there are significant differences between the group of patients with BARI 2 mg and BARI 4 mg (Mann-Whitney test). The statistical study was carried out with the SPSS15 computer package.

Results: We included 38 pts (28 women); mean age 52 ± 12 years. Pain VAS improvement for all patients, baseline pain and weeks 12. The frequency is the percentage of improvement with respect to the baseline. In BARI 2 mg group, 58% of pts (p<0.05) have experienced a decrease greater than pain VAS improvement than baseline and in BARI 4 mg group, 65% of pts (p<0.05) have experienced a decrease greater than pain VAS improvement than baseline.

No statistically significant differences were found in the two treatment groups (BARI 2 mg and BARI 4 mg) (p=0.847).

Conclusion: Our results, in general, agree with what is published in the literature (RA treated with BARI reported greater improvements in pain control when compared to adalimumab or placebo, a post-hoc analysis of the Phase 3 RA-BEAM study). BARI treated pts reported significantly greater and more rapid reductions in pain severity as measured by the pain VAS, improvements were sustained 12 weeks, without finding differences in pts receiving BARI 2 mg or BARI 4 mg.

Disclosure of Interests: None declared


AB0325 PREVALENCE OF ANXIETY/DEPRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS AT THE UNIVERSITY OF CHILE’S CLINICAL HOSPITAL AND THEIR ASSOCIATIONS WITH DISEASE ACTIVITY INDEXES AND QUALITY OF LIFE

Anne Marie Chassin-Troubert1, César Lillo1, Stephanie Prieto1, Ariel Castaño2, Hector Gatica1, Pilar Carrasco1, Francisca Bozán1, Francisca Sabugo1, Pamela Wu1, Julio Cruz1, Solvaya Saavedra1, Amelie Goecke1. Hospital Clínico Universidad de Chile, Rheumatology, Santiago, Chile; 2Hospital Clínico Universidad de Chile, OAC, Santiago, Chile

Background: Rheumatoid Arthritis is a chronic inflammatory disease with great impact in quality of life. Anxiety and depression could be frequently present in RA patients and may impact the disease activity evaluation. However psychological evaluation or therapy are not part of the standard of care of RA patients.

Objectives: To evaluate the prevalence of anxiety/depression in rheumatoid arthritis patients in control at the University of Chile’s Clinical Hospital and to investigate the association of anxiety/depression with disease activity and quality of life.

Methods: The Hospital Anxiety Depression Scale (HADS) was applied to measure depression and anxiety in a cross-section patients with RA meeting the ACR/EULAR 2010 criteria in control at the University of Chile’s Clinical Hospital. All patients included gave their informed consent. Demographic characteristics, Disease variables and activity, measure as DAS28-VHS, DAS-28 CRP, CDAI and SDAl and HAQ were evaluated at the same time. Spearmen correlation, Fisher exact test, Chi-Square and Krukal-Wallis test were used according to variables at evaluation. Statistical analysis was perform by stata v12.1 software. The study was approved by the Hospital Ethic Review board.

Results: 122 patients were enrolled in the study between december 2017 and December 2018. 103 (84.45%) were female. 56 (46%) had depression and/or anxiety according to HADS. 24% of the patients (n=24) had only depression. The severity of the depression symptoms was mild in 71% and moderate in 21% and severe in 8% of the patients. 42%, 40% and 18% of the patients with anxiety (n=55) had mild, moderate and severe anxiety symptoms respectively. The disease activity was significantly higher in patients with as compared to those without anxiety/ depression, measure with all of the following indexes: DAS28-VHS (4.43 ± 2.75, p<0.001), DAS-28 CRP (4.13 ± 2.75, p<0.001), CDAI (15 vs 7 p<0.001) and SDAl (17 vs 7.5, p<0.001). The HAQ was also significantly higher in patients with anxiety/depression (1.16 vs 0.29, p<0.01).
Conclusion: Depression/anxiety symptoms were very frequent in our cohort of RA patients. The disease activity measure with different indexes and the HAQ was significantly higher in the patients with depression/anxiety. It is possible that psychological factors influence the RA treatment outcomes. Therefore, screening and therapy of anxiety and depression should be considered in the regular management of RA patients.

REFERENCES
